Healthcare, Pharma & Life Sciences

Monteloeder's Elissara Shows Preclinical Hair-Growth Activity in New Study

Image
Monteloeder's Elissara Shows Preclinical Hair-Growth Activity in New Study

Madrid – September 06, 2026 -- Monteloeder, SL, a subsidiary of SuanNutra, SA, has published preclinical data showing its nutricosmetic ingredient Elissara® increases human dermal papilla cell proliferation to roughly 2.5 times that of untreated controls, extending the compound's known scalp benefits into follicular biology.

RedHill Buys Rebyota, Clenpiq Rights From Ferring for $12M

Raleigh, N.C. – September 06, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) has acquired exclusive global commercialization rights to Ferring Pharmaceuticals' Rebyota and exclusive U.S. rights to Clenpiq, two FDA-approved gastrointestinal drugs that together generated approximately $37.5 million in 2025 net sales.

RedHill pays $12 million upfront, fully funded by prior Talicia sale

Under the agreement, RedHill paid Ferring $12 million upfront plus tiered royalties on net sales and potential future milestones. The payment was fully covered by RedHill's previously announced $18 million divestiture of Talicia, which also carries up to $35 million in potential additional upside. Ferring retains Rebyota's manufacturing facilities and will continue supplying the product through the term of the agreement.

VALOR Network Picks RADIN Health, TMI for Federal Teleradiology

Image
VALOR Network Picks RADIN Health, TMI for Federal Teleradiology

Sheridan, Wyoming – September 06, 2026 -- VALOR Network Inc., a Service-Disabled Veteran-Owned Small Business, has selected RADIN Health's cloud-based radiology platform to power teleradiology services for the U.S. Department of Veterans Affairs and Department of War, with Total Medical Imaging supplying nationwide physician coverage through its network of more than 60 board-certified radiologists.

VALOR taps RADIN's secure cloud platform for federal imaging workflow

RADIN will deploy its radiology platform within a secure government-cloud environment built to meet federal healthcare security and operational requirements. The platform integrates enterprise imaging, PACS, RIS, intelligent worklists, diagnostic reporting, clinical communications, workflow automation, analytics and AI-assisted tools in a single system.

NYU Langone Names Frankle Chair of Psychiatry Department

Image
NYU Langone Names Frankle Chair of Psychiatry Department

NEW YORK – September 06, 2026 -- NYU Langone Health has appointed William Gordon Frankle, MD, MBA, as chair of the Department of Psychiatry at NYU Grossman School of Medicine, effective September.

Frankle succeeds Marmar after 17-year tenure

Dr. Frankle takes over from Charles R. Marmar, MD, who completed 17 years as chair and will continue as director of the Center for Precision Psychiatry within NYU Grossman School of Medicine's faculty. Frankle previously served as vice chair of the department and chief of psychiatry service at NYU Langone Hospital—Brooklyn, and holds the title of professor of psychiatry.

Orexo Reaches $4M Deal in Principle to End 6-Year DOJ Probe

Uppsala, Sweden – September 06, 2026 -- Orexo AB has reached a non-binding agreement in principle with the US Department of Justice to pay USD 4 million in installments over several years, closing a federal investigation that began in 2020.

Orexo agrees to capped contingent payment tied to 2030-2031 sales thresholds

Beyond the fixed USD 4 million payment, Orexo would accept a capped contingent payment equal to five percent of net sales, triggered only if certain sales-related thresholds are met in 2030 and 2031 and Orexo's commercial products perform successfully in the market. The company is in the final stages of negotiating the settlement but cautions there is no assurance the deal will be finalized on these terms.

Orexo Reaches Tentative $4M DOJ Settlement After 6-Year Probe

Uppsala, Sweden – September 06, 2026 -- Orexo AB has struck a non-binding agreement in principle with the US Department of Justice to settle a federal investigation that has run since 2020, the Swedish pharmaceutical company said.

Orexo to pay $4 million in installments over several years

Under the tentative terms, Orexo would pay USD 4 million in installments spread across multiple years. The company would also accept a capped contingent payment equal to five percent of net sales, triggered only if certain sales thresholds are met in 2030-2031 and contingent on Orexo's commercial products performing well in the market.

Hydreight Posts Record $28M Q2 Revenue, Up 421% Year-Over-Year

Image
Hydreight Posts Record $28M Q2 Revenue, Up 421% Year-Over-Year

Vancouver – September 06, 2026 -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) reported second-quarter 2026 revenue of $28.0 million, a 421% increase from $5.4 million a year earlier, as its VSDHOne virtual healthcare platform drove the company's strongest quarter on record.

Net income jumps to $2.5 million as pharmacy sales scale

Gross profit rose 182% to $5.4 million, while net income reached $2.5 million versus just $0.05 million in Q2 2025. Adjusted EBITDA climbed to $3.2 million from $0.2 million a year prior. Revenue grew approximately 12.5% and gross profit approximately 7% quarter-over-quarter versus Q1 2026, with net income and Adjusted EBITDA holding steady sequentially.

AAN, AHS Update Migraine Prevention Drug Guideline After 14 Years

Minneapolis – September 06, 2026 -- The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued a joint update to their 2012 clinical practice guideline on migraine prevention medications for adults, published simultaneously in Neurology and Headache journals on September 06, 2026.

Guideline sets clear treatment threshold for clinicians

The update recommends preventive treatment for patients experiencing four or more migraine days per month, four or more moderate-to-severe headache days per month, or migraine that impairs their ability to work or complete daily tasks. It distinguishes between chronic migraine, defined as 15 or more headache days a month with at least eight showing migraine features, and episodic migraine, which occurs on fewer days per month.

Canada's Drug Agency Backs Public Reimbursement of Alzheimer's Drug Leqembi

STOCKHOLM – September 06, 2026 -- Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease, BioArctic AB's partner Eisai announced.

Final recommendation follows agency reconsideration process

The decision comes after CDA-AMC reconsidered its position on the drug, marking a step toward broader patient access in Canada. Negotiations will now proceed through the pan-Canadian Pharmaceutical Alliance, followed by individual reimbursement decisions from public drug plans across Canada's provinces and territories.

Greenway Posts 38% Revenue Growth, Record Grams Sold in Q1 F2027

Image
Greenway Posts 38% Revenue Growth, Record Grams Sold in Q1 F2027

Kingsville, ON – September 06, 2026 -- Greenway Greenhouse Cannabis Corporation (CSE: GWAY) (OTCQB: GWAYF) reported net revenue of CA$2.23 million for the three months ended September 06, 2026, up 38% from CA$1.62 million a year earlier, while grams sold hit a record 2.33 million, an 8% increase over the prior high.

Cash cost per gram falls 30% to CA$0.69 as production efficiency improves

The company generated CA$36,778 in cash from operating activities, reversing a cash outflow of CA$865,538 in the same quarter last year. Adjusted EBITDA came in positive at CA$47,900, even as net loss and comprehensive loss totaled CA$659,893. Gross margin before fair value adjustments narrowed to 12%, reflecting a lower average net sales price of CA$0.96 per gram, or CA$1.30 per gram excluding inventory tied to discontinued cultivars.